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Background: The Japan Lung Cancer Society, the Japanese Asso-
ciation for Chest Surgery, and the Japanese Respiratory Society
jointly established the Japanese Joint Committee for Lung Cancer
Registration, which has regularly conducted lung cancer registries
for surgical cases in 5-year periods. We analyzed data obtained in
these registries to reveal the most recent surgical outcomes and
trends related to lung cancer surgery in Japan.
Methods: Using data from the registry in 2010 for cases of surgery
performed in 2004, demographics, surgical results, and stage-spe-
cific prognoses were analyzed. In addition, trends for those param-
eters over 10 years were assessed.
Results: The 5-year survival rate for all cases (n  11,663, 7369
males, mean age 66.7 years) was 69.6%. The 5-year survival rates
by c-stage and p-stage were as follow: IA, 82.0% (n  6295) and
86.8% (n  4978); IB, 66.8% (n  2339) and 73.9% (n  2552);
IIA, 54.5% (n  819) and 61.6% (n  941); IIB, 46.4% (n  648)
and 49.8% (n  848); IIIA, 42.8% (n  1216) and 40.9% (n 
1804); IIIB, 40.3% (n  90) and 27.8% (n  106); and IV, 31.4%
(n  256) and 27.9% (n  434), respectively. The percentages of
female patients, cases with adenocarcinoma, stage I or II disease,
and tumors sized less than 2 cm were increased, while those of
operative and hospital deaths were decreased. Furthermore, the
prognoses of all cases and cases in each stage improved over the
decade.
Conclusion: In Japanese cases of lung cancer surgery, demograph-
ics, surgical results, and stage-specific prognoses changed over the
10-year study period, while the 5-year survival rate for surgical
cases improved to 69.6% in 2004.
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(J Thorac Oncol. 2011;6: 1229–1235)
Lung cancer is one of the leading causes of death in mostindustrial countries.1 As such, it is crucial to understand
the demographics, tumor-specific backgrounds, and progno-
ses by related factors and stage. In addition, elucidation of
trends for those parameters is helpful to compose strategies
for lung cancer treatment.
The Japan Lung Cancer Society, the Japanese Associ-
ation for Chest Surgery, and the Japanese Respiratory Society
jointly established the Japanese Joint Committee of Lung
Cancer Registry (JJCLCR), which has regularly conducted
nationwide registrations every 5 years for cases treated sur-
gically, with the results of cases treated in 1994 and 1999
published in English in 1999 and 2004, respectively.2,3 Fur-
thermore, additional studies related to specific issues encoun-
tered in registries for surgical cases in 1999, such as octoge-
narian cases,4 pleural invasion,5 gender,6 and surgical
results,7 have been published. In addition to the regular
registries, prospective enrollment and retrospective analyses
of surgical and nonsurgical cases treated in 2002 were per-
formed and the results published.8 However, the investigated
points regarding preoperative parameters are limited in that
registry and fewer than those noted in the regular registry for
surgical cases conducted every 5 years.
A new regular nationwide registry for lung cancer cases
surgically treated in 2004 in Japan was conducted in 2010 by
the JJCLCR. This registry investigated detailed tumor node
metastasis (TNM) factors, thus it was possible to analyze the
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data using UICC-TNM ver. 7 (2009).9 In this study, we
analyzed data obtained by these registries to reveal the most
recent surgical outcomes and trends related to lung cancer
surgery in Japan.
PATIENTS AND METHODS
The JJCLCR conducted a retrospective observational
study of patients who underwent surgery for lung cancer
between January 1, 2004, and December 31, 2004. The
committee asked the 605 teaching hospitals certified by
the Japanese Board of General Thoracic Surgery to join the
study, of which 253 (41.3%) participated. This registry was
opened on January 1, 2010, and closed on June 31, 2010. In
addition, 303 institutes (the number of invited institutes is
unknown) participated in the registry for cases in 1994 that
was performed in 2000, and 386 (75.2%) of 513 invited
institutes participated in the registry for cases in 1999 that
was performed in 2005.
The participating institutions took part in this registry
by accessing a web site established by the JJCLCR, after
receiving information that had been mailed to the 605 teach-
ing hospitals. Each participating institute was sent a universal
serial bus (USB) flash memory stick that contained software
to be used for the registry. Each institute was authorized to
use the registration form in the server located at the JJCLCR
office after entering their ID and password, which was also
mailed to the institution.
For these procedures, the JJCLCR used the secure
sockets layer protocol for communication and digest (most
reliable) certification, which was considered to be more
secure than postal mail. The data sheet containing the pa-
tient’s ID and registration no., used for anonymity in a
linkable fashion, was kept in the USB flash memory stick and
placed in a location that could be locked by each participating
institution. In addition, each USB flash memory stick was
coded with an individual serial key sent from the JJCLCR
office and known only by the institution. The JJCLCR com-
pleted confirmation of participation in the registry by the end
of 2009 and distributed the USB flash memory sticks to the
institutions in 2009.
This registry followed the ethical guidelines for epide-
miologic studies published jointly by the Japan Ministry of
Science, Culture, and Education and the Japan Ministry of
Health, Labor, and Welfare on June 17, 2002, which was
revised on August 16, 2007. In addition, it was approved by
the institutional review board of Osaka University Medical
Hospital, where the registry office is located, after discussions
published on August 13, 2009 (approval no. 09124).
Inclusion criteria were as follows: (1) pathological
(including cytology findings) diagnosis of any type of lung
cancer at a participating institution; (2) diagnosis obtained in
2004; and (3) treated by surgery. Patients with lung cancer
recurrence or metastasis were excluded. The following points
were investigated: (1) demographic background, (a) date of
registry, (b) gender, (c) birth month and year, (d) date of
diagnosis; (2) preoperative status, (a) Eastern Cooperative
Oncology Group performance status (PS), (b) preoperative
comorbidity, (c) smoking status, (d) status of serum tumor
markers (CEA, SCC or CYFRA, SLX and NSE or Pro-GRP);
(3) clinical T factors, (a) tumor size, (b) status of invasion at
the main bronchus, (c) pleural invasion, (d) intrapulmonary
metastasis, (e) status of pleural effusion, (f) status of atelec-
tasis, (g) status of invaded organ; (4) clinical N factor (status
of lymph nodes); (5) clinical M factor (metastasized organ);
(6) surgery, (a) induction therapy, (b) operation, (c) place of
tumor origin, (d) extent of lymph node removal, (e) gross
curative status, (f) status of residual rumor, (g) lavage cytol-
ogy findings, (h) combined resection; (7) postoperative mor-
bidity; (8) tumor histology; (9) adjuvant therapy; (10) path-
ological T factors, (a) tumor size, (b) extent of bronchial
involvement, (c) pleural invasion, (d) intrapulmonary metas-
tasis, (e) status of pleural effusion, (f) pleural dissemination,
(g) status of pleural effusion, (h) status of atelectasis, (i)
status of invaded organ; (11) pathological N factor (status of
removal of and metastasis to each lymph node); and (12)
pathological M factor (metastasized organ). The extent of
resection (exploration, R0, R1, or R2) was also registered.
Tumor size, detailed T factors, and lymph node status
were classified using both UICC-TNM ver. 6 (1999)10 and
UICC-TNM ver. 7 (2009).9 For this classification, the #10
lymph node of the Naruke map was converted to #7 of
UICC-TNM ver. 7 (2009). To comprehend demographic and
prognostic alterations over a decade, data from the Japanese
nationwide registries in 1994 and 1999 are also presented.
The data quoted were taken from official reports of the
JJCLCR published in 200211 and 2005.12 Data from the
submitted cases were stored and converted to excel files,
which were transferred to a JJCLCR member biological
statistician (E.M.), who independently reviewed the files for
cases from 1994, 1999, and 2004. The follow-up period was
defined as the time from the date of surgery to the latest
follow-up examination. Survival period was defined as the
number of months from the day of surgery to the day of death
or the latest day of confirmed survival. Cases of death
immediately after the operation were included. Survival
curves were estimated according to the Kaplan-Meier method
for the subsets clinical stage, pathological stage, sex, and
histological subtype of tumor. Differences in survival were
tested using the log-rank method. A p value less than 0.05
was considered to be statistically significant.
RESULTS
The number of registered cases was 11,663, which were
provided by 253 institutions. Demographic backgrounds are
shown in Table 1. In 2004, there were 7369 males and 4294
females registered, with a mean age of 66.7 years (range,
14–91), a follow-up period that ranged from 2 to 78 months
(median, 58 months), and a percentage of PS 0 or 1 of 96.7%.
The rates of female patients, mean age, and percentage of PS
0 or 1 showed increasing trends. As shown in Table 2, the
most frequent tumor histology in 2004 was adenocarcinoma,
followed by squamous cell carcinoma, although the ratio of
adenocarcinoma was increasing and that of squamous cell
carcinoma was decreasing. Induction chemotherapy was per-
formed in 518 (4.4%) and adjuvant therapy in 2903 (24.9%)
cases. The rate of anti-epidermal growth factor receptor is
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unknown, as it was not noted. The rate of R0 was 93.6% in
2004, 88.5% in 1999, and 80.4% in 1994. In addition, the
5-year survival rate (5-YSR) for each histology type im-
proved. Moreover, the rate of small-sized tumor cases was
also increasing, as the rates of tumors sized less than 1 and 2
cm were 9.1% and 36.9%, respectively (Table 3).
Clinical and pathological TNM factors based on UICC-
TNM ver. 6 (1999) are shown in Table 4. In 2004, clinical T1
diseases comprised more than half of the cases, and the rate
of clinical N0 disease was greater than 80%. Both showed
increasing trends as compared with the 1999 results. Further-
more, a similar trend was shown in the pathological classifi-
cation based on UICC-TNM ver. 6 (1999). Clinical and
pathological stages based on UICC-TNM ver. 7 (2009) are
shown in Table 5, while the distributions of clinical and
pathological stages based on UICC-TNM ver. 6 (1999) and
UICC-TNM ver. 7 (2009) are presented in Table 6. In 2004,
the rate of clinical stage IA disease was greater than 50%,
while that of pathological IA disease was less than 50%.
The trends for survival for all cases and each stage are
also shown in Table 6. In 2004, the 5-YSR for all cases was
69.6%, which showed an improving trend for both total cases
and each stage. The c-stage and p-stage (UICC-TNM ver. 7,
2009) specific 5-YSRs were as follows: IA, 82.0% (n 
6295) and 86.8% (n  4978); IB, 66.8% (n  2339) and
73.9% (n  2552); IIA, 54.5% (n  819) and 61.6% (n 
941); IIB, 46.4% (n  648) and 49.8% (n  848); IIIA,
42.8% (n  1216) and 40.9% (n  1804); IIIB, 40.3% (n 
90) and 27.8% (n  106); and IV, 31.4% (n  256) and
27.9% (n  434), respectively (Table 7). The survival curves
based on clinical and pathological stages determined with the
modified UICC-TNM ver. 7 (2009) are shown in Figures 1
and 2, respectively. For clinical stage, there were no
TABLE 1. Demographics
2004
n (%)
1999
n (%)
1994
n (%)
Total 11,663 (100.0) 13,344 (100.0) 7393 (100.0)
Gender
Male 7369 (63.2) 8878 (66.5) 5154 (69.7)
Female 4294 (36.8) 4344 (32.6) 2197 (29.7)
Missing 0 (0.0) 122 (0.9) 42 (0.6)
Age (yr)
10–19 4 (0.0) 9 (0.1) 2 (0.0)
20–29 12 (0.1) 15 (0.1) 17 (0.2)
30–39 85 (0.7) 122 (0.9) 84 (1.1)
40–49 495 (4.2) 731 (5.5) 512 (6.9)
50–59 2065 (17.7) 2312 (17.3) 1334 (18.0)
60–69 3713 (31.8) 4610 (34.5) 2984 (40.4)
70–79 4584 (39.3) 4823 (36.1) 2222 (30.1)
80–89 701 (6.0) 598 (4.5) 232 (3.1)
90 4 (0.0) 4 (0.0) 1 (0.0)
Missing 0 (0.0) 120 (0.9) 5 (0.1)
Mean  SD 66.7  9.9 65.8  9.8 64.5  9.7
Performance status
0 9608 (82.4) 10158 (76.1) NA
1 1688 (14.5) 2319 (17.4) NA
2 154 (1.3) 230 (1.7) NA
3 34 (0.3) 21 (0.2) NA
4 1 (0.0) 0 (0.0) NA
Unknown 178 (1.5) 0 (0.0) NA
Missing 0 (0.0) 616 (4.6) NA
NA, not assessed.
TABLE 2. Tumor Histology and Survival
2004 1999 1994
n (%) 5-YSR (%) n (%) 5-YSR (%) n (%) 5-YSR (%)
Total 11,663 (100.0) 13,344 (100.0) 7393 (100.0)
Tumor histology
Adenocarcinoma 7921 (67.9) 74.9 8239 (61.7) 67.3 4116 (55.7) 56.0
Squamous cell carcinoma 2600 (22.3) 59.1 3700 (27.7) 52.3 2441 (33.0) 48.6
Large cell carcinoma 387 (3.3) 53.3 474 (3.6) 45.5 266 (3.6) 46.7
Adenosquamous cell carcinoma 225 (1.9) 50.8 207 (1.6) 42.1 185 (2.5) 35.7
Small cell carcinoma 243 (2.1) 52.6 390 (2.9) 48.1 248 (3.4) 36.7
Others 224 (2.0) NA 265 (2.0) NA 129 (1.8) NA
Missing 0 (0.0) 69 (0.5) 8 (0.1)
NA, not assessed; 5-YSR, 5-year survival rate.
TABLE 3. Tumor Size in Detail
Tumor
Size (cm)
2004
1999
n (%)
1994
n (%)
Clinical
n (%)
Pathological
n (%)
1.0 983 (8.4) 1057 (9.1) 746 (5.6) 249 (3.4)
1.1–1.5 1352 (11.6) 1459 (12.5) 1227 (9.2) 526 (7.1)
1.6–2.0 2038 (17.5) 1787 (15.3) 1972 (14.8) 942 (12.7)
2.1–2.5 1599 (13.7) 1730 (14.8) 1824 (13.7) 952 (12.9)
2.6–3.0 1409 (12.1) 1336 (11.5) 1527 (11.4) 926 (12.5)
3.1–4.0 2248 (19.3) 2091 (17.9) 2693 (20.2) 1621 (21.9)
4.1–5.0 970 (8.3) 1014 (8.7) 1426 (10.7) 887 (12)
5.1–6.0 468 (4.0) 497 (4.3) 740 (5.5) 510 (6.9)
6.1–7.0 358 (3.1) 375 (3.2) 949 (7.1) 727 (9.8)
7.1 238 (2.0) 317 (2.7)
Missing 0 (0.0) 0 (0.0) 240 (1.8) 53 (0.7)
Total 11,663 (100.0) 11,663 (100.0) 13,344 (100.0) 7393 (100.0)
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statistically significant differences between IIB and IIIA
(p  0.5), IIIA and IIIB (p  0.7), IIB and IIIB (p  0.5),
and IIIB and IV (p  0.08), whereas for pathological stage,
there was no statistically significant difference between
IIIB and IV (p  0.9).
Postoperative morbidity and mortality are shown in
Table 8. In 2004, the rate of severe postoperative compli-
cations (greater than National Cancer Institute Common
Toxicity Criteria grade 3) had decreased from the former
registry in 1999. Furthermore, the rate of operation-related
deaths showed a decreasing trend, as the percentage of
operative deaths (death within 30 days after the operation)
was 0.4% and that of hospital deaths was 0.4% in the 2004
registry.
DISCUSSION
In cases of lung cancer that underwent surgery in Japan,
demographics and stage-specific prognoses changed in the
decade studied. In that time period, the percentages for
female patients, adenocarcinoma, small-sized tumors (2
cm), and aged patients increased, whereas the rate of surgery-
related deaths decreased to only 0.8%. With those changes,
the 5-YSR in 2004 of all lung cancer patients who underwent
surgery was 69.6%.
A retrospective study of a large number of surgical
cases carried out by JJCLRC in 2004 showed that gender is
a prognostic indicator.3 A more detailed analysis using the
same registry data showed that women with non-small cell
lung cancer, especially with adenocarcinoma histology, had
better survival than men and were more likely to have stage
TABLE 4. TNM Distribution by UICC-TNM ver. 6 (1999)
2004
n (%)
1999
n (%)
1994
n (%)
Total 11,663 (100.0) 13,344 (100.0) 7393 (100.0)
c-T ver. 6
T1 6780 (58.1) 6586 (49.4) 3162 (42.8)
T2 3840 (32.9) 5066 (38.0) 3092 (41.8)
T3 659 (5.7) 1111 (8.3) 786 (10.6)
T4 384 (3.3) 521 (3.9) 317 (4.3)
TX 60 (0.4) 14 (0.2)
Missing 22 (0.3)
c-N ver. 6
N0 9733 (83.5) 10,164 (76.2) 4904 (66.3)
N1 936 (8.0) 1211 (9.1) 874 (11.8)
N2 939 (8.1) 1789 (13.4) 1458 (19.7)
N3 55 (0.5) 99 (0.7) 131 (1.8)
NX 0 (0.0) 81 (0.6) 26 (0.3)
c-M ver. 6
M0 11,458 (98.2) 13,022 (97.6) 7208 (97.5)
M1 131 (1.1) 210 (1.6) 167 (2.3)
MX 74 (0.6) 112 (0.8) 14 (0.2)
p-T ver. 6
T1 6459 (55.4) 6022 (45.1) 2925 (39.6)
T2 3685 (31.6) 4654 (34.9) 2854 (38.6)
T3 703 (6.0) 1120 (8.4) 781 (10.6)
T4 816 (7.0) 1217 (9.1) 771 (10.4)
TX 131 (1.0) 35 (0.5)
Missing 0 (0.0) 200 (1.5) 27 (0.4)
p-N ver. 6
N0 8932 (76.6) 9163 (68.7) 4464 (60.4)
N1 1133 (9.7) 1587 (11.9) 980 (13.3)
N2 1550 (13.3) 2333 (17.5) 1616 (21.9)
N3 48 (0.4) 140 (1.0) 126 (1.7)
NX 201 (1.8)
Missing 0 (0.0) 121 (0.9) 6 (0.1)
p-M ver. 6
M0 11,407 (97.8) 12,838 (96.2) 7092 (95.9)
M1 188 (1.6) 407 (3.1) 275 (3.7)
Mx 68 (0.6) 18 (0.2)
Missing 0 (0.0) 99 (0.7) 8 (0.1)
TNM, tumor, node, metastasis.
TABLE 5. TNM Distribution by Modified UICC-TNM ver. 7
(2009)
2004
n (%)
c-T ver. 7
T1a 4147 (35.6)
T1b 2649 (22.7)
T2a 3191 (27.4)
T2b 509 (4.4)
T3 1008 (8.6)
T4 159 (1.4)
c-N ver. 7
N0 9733 (83.5)
N1 764 (6.6)
N2 1111 (9.6)
N3 55 (0.5)
c-M ver. 7
M0 11,337 (97.2)
M1a 177 (1.5)
M1b 79 (0.7)
Mx 70 (0.6)
p-T ver. 7
T1a 3598 (30.9)
T1b 2051 (17.6)
T2a 3887 (33.3)
T2b 533 (4.6)
T3 1376 (11.8)
T4 218 (1.9)
p-N ver. 7
N0 8932 (76.6)
N1 908 (7.8)
N2 1775 (15.2)
N3 48 (0.4)
p-M ver. 7
M0 11,166 (95.7)
M1a 345 (3.0)
M1b 89 (0.8)
Mx 63 (0.5)
For the N classification, all #10 lymph nodes in the Naruke map were converted to
#7 in UICC-TNM ver. 7 (2009).
TNM, tumor, node, metastasis.
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IA disease, which might account for their better prognosis.6
However, another study of propensity score-matched gender
patients found no survival advantage.13 Thus, the increase in
number of females with adenocarcinoma may have contrib-
uted to the improvement of survival rate in the current
JJCLCR registry.
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FIGURE 1. Clinical stage-specific survival curves by UICC-
TNM ver. 7 (2009). The log-rank test results were not signifi-
cantly different between IIB and IIIA (p  0.5), IIIA and IIIB
(p  0.7), IIB and IIIB (p  0.5), and IIIB and IV (p  0.08).
For the N classification, all #10 lymph nodes in the Naruke
map were converted to #7 in UICC-TNM ver. 7 (2009).
TABLE 6. Stage Distribution and Specific Survival by UICC-TNM ver. 6 (1999)
Ver. 6
2004 1999 1994
n (%) 5-YSR (%) n (%) 5-YSR (%) n (%) 5-YSR (%)
Total 11,663 69.6 13,344 61.6 7238 51.9
C-stage
IA 6295 (54) 82 5939 (45) 77 2618 (30.2) 71.5
IB 2788 (23.9) 63.4 3242 (24.5) 60.1 1646 (23) 50.1
IIA 203 (1.7) 55.4 226 (1.7) 53.8 169 (2.4) 47.8
IIB 899 (7.7) 48.6 1304 (9.9) 43.6 793 (11.1) 40.4
IIIA 940 (8.1) 43.3 1723 (13) 38 1385 (19.3) 34.6
IIIB 407 (3.5) 41.6 567 (4.3) 33.6 395 (5.5) 27.6
IV 131 (1.1) 29.1 211 (1.6) 27 162 (2.3) 19.9
Missing 0 (0) 132 (1) 70
P-stage
IA 5611 (48.1) 85.9 5007 (38.2) 83.3 2142 (30.4) 79.2
IB 2398 (20.4) 69.3 2803 (21.4) 66.4 1488 (21.1) 60.1
IIA 336 (2.9) 60.9 400 (3) 60.1 261 (3.7) 58.6
IIB 977 (8.4) 51.1 1388 (10.6) 47.2 785 (11.1) 42.2
IIIA 1354 (11.6) 41 1944 (14.8) 32.8 1337 (19) 28.4
IIIB 799 (6.9) 36.7 1179 (9) 30.4 759 (10.8) 20
IV 188 (1.6) 27.8 397 (3) 23.2 275 (3.9) 19.3
Missing 0 (0) 226 (1.7) 191 (2.6)
TNM, tumor, node, metastasis; 5-YSR, 5-year survival rate.
TABLE 7. Stage Distribution and Specific Survival by
Modified UICC-TNM ver. 7 (2009)
Ver. 7
2004
n (%) 5-YSR (%)
Total 11,663 69.6
C-stage
IA 6295 (54) 82
IB 2339 (20.1) 66.1
IIA 819 (7) 54.5
IIB 648 (5.6) 46.4
IIIA 1216 (10.4) 42.8
IIIB 90 (0.1) 40.3
IV 256 (2.2) 31.4
Missing 0 (0)
P-stage
IA 4978 (42.7) 86.8
IB 2552 (21.9) 73.9
IIA 941 (8.1) 61.6
IIB 848 (7.3) 49.8
IIIA 1804 (15.5) 40.9
IIIB 106 (0.9) 27.8
IV 434 (3.7) 27.9
Missing 0 (0)
For the N classification, all #10 lymph nodes in the Naruke map were converted to
#7 in UICC-TNM ver. 7 (2009).
TNM, tumor, node, metastasis; 5-YSR, 5-year survival rate.
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Alteration of tumor size may also have contributed to
survival in the JJCLCR registry. Tumor size itself is a
prognostic factor, as that less than 2.0 cm was reported to
be an indicator of good survival in N0M0 patients in the
International Association for the Study of Lung Cancer
staging project presented in 2007, in which the 5-YSR was
77%.14 Thus, a tumor sized less than 2.0 cm is classified as
T1a in UICC-TNM ver. 7 (2009).6 In the current Japanese
registry of surgical cases treated in 2004, pathological
findings showed that the ratio of tumors sized less than 2.0
cm was 36.9% and that of those less than 1.0 cm in size
was 9.1%, which indicated a gradual increase from 1994
and might be attributable to recent widespread use of
computed tomography in Japan.15
In our study, the percentage of patients older than 70
years gradually increased from 1994. The 5-YSR of those
aged patients was worse than that of younger patients.3,7
However, the 5-YSR of aged patients is improving,7 while
their number has been estimated to increase in the future.16
The contribution of those changes to the prognosis of patients
with lung cancer who undergo surgery must be carefully
watched.
Regardless of the increasing number of patients older
than 70 years, the postoperative mortality and morbidity rates
improved in the recent registry of surgical cases in Japan.
This improvement may be related to the increase in cases of
small-sized early-stage lung cancer, which can be treated by
less invasive surgery. Furthermore, the decrease in percent-
age of postoperative deaths may also contribute to the recent
trend of good survival.
The results of the current registry of surgical cases
treated in 2004 in Japan include data from selected edu-
cational hospitals that participated in the registry. How-
ever, clinical diagnosis methods have recently changed,
including widespread use of PET-CT, thus selection bias
and “Will Rogers phenomenon” should be considered.
Nevertheless, the data presented here provide an important
reference source, as a large number of patients were
registered and analyzed.
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